NOTE 11:—SELECTED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

The Company's business is currently comprised of one operating segment. The nature of the products and services provided by the Company and the type of customers for these products and services are similar. Operations in Israel and the United States include research and development, sales and marketing and business development. The Company follows ASC 280, "Segment Reporting". Total revenues are attributed to geographic areas based on the location of the end customer.

a.The following represents the total revenue and long-lived assets for the years ended December 31, 2016 and 2015:

	Year ended December 31, 2016		Year ended December 31, 2015
Licensing Revenue:
Europe	$	1,065	$	869

Total revenue	$	1,065	$	869

	December 31,
	2016		2015
Long-lived assets:
Israel	$	375	$	372
United States		330		380
United Kingdom		3,075		1,466
France		61		61
Switzerland		708		304

Total long-lived assets	$	4,549	$	2,583

	Year ended December 31, 2016			Year ended December 31, 2015
Sales to a single customer exceeding 10%:
Cardiome		100	%		100	%

b.Financial expense (income), net:

	Year ended December 31,
	2016			2015
Financial expenses:
Interest expense and bank fees	$	97		$	77
Issuance costs allocated to warrants		784			—

	$	881		$	77
Financial income:
Interest income	$	(74	)	$	(50	)
Reevaluation of fair value of warrants to purchase Convertible Preferred Shares		—			(40	)
Reevaluation of fair value of warrants to purchase Ordinary Shares		(2,491	)		—
Foreign currency translation adjustments		(217	)		(75	)

	$	(2,782	)	$	(165	)

Total financial income, net	$	(1,901	)	$	(88	)

c.The net loss and the weighted average number of shares used in computing basic and diluted net loss per share for the years ended December 31, 2016 and 2015, is as follows:

	Year ended December 31,
	2016		2015
Numerator:
Net loss	$	25,869	$	24,971
Dividends accumulated for the period(*)		—		988

Net loss available to shareholders of Ordinary Shares	$	25,869	$	25,959


Denominator:
Weighted average number of Ordinary Shares used in computing basic and diluted net loss per share		16,253,975		10,593,227

(*)	The net loss used for the computation of basic and diluted net loss per share include the compounded dividend of eight percent per annum which shall be distributed to shareholders in case of distributable assets determined in the AOA under the liquidation preference right.

Convertible securities such as warrants to purchase Series Preferred A2, D, E1 Shares, Series Preferred A1, A2, B, C, D, E Shares and options, have not been taken into account due to their anti-dilutive effect.